
Coya Therapeutics, Inc. — Investor Relations & Filings
Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops proprietary biologics and multi-modality therapies designed to enhance the function of regulatory T cells (Tregs). The company's approach focuses on modulating dysfunctional Tregs to suppress inflammation associated with neurodegenerative, autoimmune, and metabolic diseases. Its lead product candidate, COYA 302, is an investigational biologic combination therapy being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). The pipeline also includes other candidates such as COYA 303, a combination of low-dose Interleukin-2 (IL-2) and a GLP-1 receptor agonist, intended for inflammation-driven diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-13 | English | |
| DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-13 | English | |
| 8-K - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | |
| 424B5 - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | |
| 10-Q - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | |
| 8-K - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45589489 | ARS - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-13 | English | ||
| 45588995 | DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-13 | English | ||
| 45268238 | 8-K - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | ||
| 45266702 | 424B5 - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | ||
| 45246121 | 10-Q - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | ||
| 45244496 | 8-K - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-05-12 | English | ||
| 33157224 | 8-K - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-04-02 | English | ||
| 33012250 | EFFECT - Coya Therapeutics, Inc. (0001835022) (Filer) | 2026-03-23 | English | ||
| 31987353 | 8-K Filing | 2026-01-30 | English | ||
| 31987344 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
| 31987320 | SCHEDULE 13G/A Filing | 2026-01-28 | English | ||
| 13347572 | 4 | 2026-01-26 | English | ||
| 13347573 | 4 | 2026-01-26 | English | ||
| 13347576 | 4 | 2026-01-26 | English | ||
| 13347577 | 4 | 2026-01-26 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
Coya Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34219/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34219 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34219 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34219 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34219}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Coya Therapeutics, Inc. (id: 34219)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.